Millennium Management LLC Sells 479,040 Shares of 1-800-PetMeds (PETS)

Millennium Management LLC cut its position in 1-800-PetMeds (NASDAQ:PETS) by 98.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,115 shares of the company’s stock after selling 479,040 shares during the quarter. Millennium Management LLC’s holdings in 1-800-PetMeds were worth $324,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PETS. LS Investment Advisors LLC boosted its stake in 1-800-PetMeds by 283.5% in the 4th quarter. LS Investment Advisors LLC now owns 2,861 shares of the company’s stock valued at $130,000 after purchasing an additional 2,115 shares during the period. Sterling Investment Advisors Ltd. boosted its stake in 1-800-PetMeds by 118.5% in the 4th quarter. Sterling Investment Advisors Ltd. now owns 2,950 shares of the company’s stock valued at $134,000 after purchasing an additional 1,600 shares during the period. CenterStar Asset Management LLC bought a new stake in 1-800-PetMeds in the 4th quarter valued at $169,000. OppenheimerFunds Inc. bought a new stake in 1-800-PetMeds in the 4th quarter valued at $202,000. Finally, Weatherly Asset Management L. P. bought a new stake in 1-800-PetMeds in the 4th quarter valued at $212,000. Institutional investors and hedge funds own 91.84% of the company’s stock.

Several analysts recently issued reports on the company. Zacks Investment Research upgraded 1-800-PetMeds from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research note on Wednesday, May 9th. ValuEngine downgraded 1-800-PetMeds from a “buy” rating to a “hold” rating in a research report on Tuesday, May 8th. BidaskClub downgraded 1-800-PetMeds from a “buy” rating to a “hold” rating in a research report on Wednesday, April 18th. Finally, Craig Hallum cut their target price on 1-800-PetMeds to $38.00 and set a “hold” rating for the company in a research report on Tuesday, May 8th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $40.00.

NASDAQ:PETS opened at $35.85 on Monday. The firm has a market cap of $738.55 million, a PE ratio of 19.70, a P/E/G ratio of 1.57 and a beta of 1.03. 1-800-PetMeds has a fifty-two week low of $31.81 and a fifty-two week high of $57.80.

1-800-PetMeds (NASDAQ:PETS) last released its earnings results on Monday, May 7th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.03. The firm had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.43 million. 1-800-PetMeds had a return on equity of 34.76% and a net margin of 13.62%. The company’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.37 EPS. sell-side analysts anticipate that 1-800-PetMeds will post 2.28 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, May 25th. Stockholders of record on Friday, May 18th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, May 17th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.79%. 1-800-PetMeds’s payout ratio is 54.95%.

1-800-PetMeds Profile

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It provides non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes.

Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 1-800-PetMeds (NASDAQ:PETS).

Institutional Ownership by Quarter for 1-800-PetMeds (NASDAQ:PETS)

Receive News & Ratings for 1-800-PetMeds Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 1-800-PetMeds and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply